ArticleJournal of virology1998
Characterization of the proline-rich region of murine leukemia virus envelope protein.
Article in Journal of virology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 62 citations in OpenAlex.
- Cell cycle checkpoint control: The cyclin G1/Mdm2/p53 axis emerges as a strategic target for broad-spectrum cancer gene therapy - A review of molecular mechanisms for oncologists.Molecular and clinical oncology · 2018Article
- Sequence Diversity, Intersubgroup Relationships, and Origins of the Mouse Leukemia Gammaretroviruses of Laboratory and Wild Mice.Journal of virology · 2016Article
- Library screening and receptor-directed targeting of gammaretroviral vectors.Future microbiology · 2013Review
- Evolution of the hepatitis E virus hypervariable region.The Journal of general virology · 2012Article
- Phylogenetic and biological analysis of a laboratory-generated gammaretrovirus xenotropic murine leukemia virus-related virus (XMRV).Virus genes · 2012Article
- Detailed mapping of determinants within the porcine endogenous retrovirus envelope surface unit identifies critical residues for human cell infection within the proline-rich region.Journal of virology · 2012Article
- Vpu-dependent block to incorporation of GaLV Env into lentiviral vectors.Retrovirology · 2010Article
- Molecular and phylogenetic analyses of a new amphotropic murine leukemia virus (MuLV-1313).Virology journal · 2006Article
- Stoichiometry of murine leukemia virus envelope protein-mediated fusion and its neutralization.Journal of virology · 2006Article
- Effect of epitope position on neutralization by anti-human immunodeficiency virus monoclonal antibody 2F5.Journal of virology · 2006Article
- Mutations of a residue within the polyproline-rich region of Env alter the replication rate and level of cytopathic effects in chimeric avian retroviral vectors.Journal of virology · 2005Article
- The fusion-controlling disulfide bond isomerase in retrovirus Env is triggered by protein destabilization.Journal of virology · 2005Article
- Determinants of high titer in recombinant porcine endogenous retroviruses.Journal of virology · 2004Article
- Tagging retrovirus vectors with a metal binding peptide and one-step purification by immobilized metal affinity chromatography.Journal of virology · 2004Article
- Change of tropism of SL3-2 murine leukemia virus, using random mutational libraries.Journal of virology · 2004Article
- An aromatic side chain is required at residue 8 of SU for fusion of ecotropic murine leukemia virus.Journal of virology · 2004Article
- G541R within the 4070A TM protein regulates fusion in murine leukemia viruses.Journal of virology · 2003Article
- Role of the mutation Q252R in activating membrane fusion in the murine leukemia virus surface envelope protein.Journal of virology · 2003Article
- Distinct mechanisms of neutralization by monoclonal antibodies specific for sites in the N-terminal or C-terminal domain of murine leukemia virus SU.Journal of virology · 2003Article
- Characterization of a cytolytic strain of equine infectious anemia virus.Journal of virology · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Mammalian type C retroviral envelope proteins contain a variable proline-rich region (PRR), located between the N-terminal receptor-binding domain and the more highly conserved C-terminal portion of the surface (SU) subunit. We have investigated the role of the PRR in the function of murine leukemia virus (MuLV) envelope protein. In the MuLVs, the PRR contains a highly conserved N-terminal sequence and a hypervariable C-terminal sequence. Despite this variability, the amphotropic PRR could functionally substitute for the ecotropic PRR. The hypervariable region of the PRR was not absolutely required for envelope protein function. However, truncations in this region resulted in decreased levels of both the SU and TM proteins in viral particles and increased amounts of the uncleaved precursor protein, Pr85. In contrast, the N-terminal conserved region was essential for viral infectivity. Deletion of this region prevented the stable incorporation of envelope proteins into viral particles in spite of normal envelope protein processing, wild-type levels of cell surface expression, and a wild-type ability to induce syncytia in an XC cell cocultivation assay. However, higher levels of the SU protein were shed into the supernatant, suggesting a defect in SU-TM interactions. Our data are most consistent with a role for the PRR in stabilizing the overall structure of the protein, thereby affecting the proper processing of Pr85, SU-TM interactions, and the stable incorporation of envelope proteins into viral particles. In addition, we have demonstrated that the PRR can tolerate the insertion of a peptide-binding domain, making this a potentially useful site for constructing targetable retroviral vectors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.